Overview
Tirzep 10 mg is a breakthrough metabolic formulation containing Tirzepatide, a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Developed by ACI Pharmaceuticals PLC and distributed internationally by Saif Pharma, Tirzep represents a major paradigm shift in diabetes and weight management. It consists of a 39-amino-acid modified peptide engineered with a C20 fatty diacid moiety that facilitates albumin binding, prolonging its half-life to support a highly effective, once-weekly dosing profile.
Please note: While sometimes referred to broad-spectrum as “tablets” in digital catalogs, Tirzep is structurally a therapeutic peptide supplied exclusively as a sterile solution for subcutaneous injection to preserve molecular integrity.
Therapeutic Applications
Tirzep 10 mg is indicated for:
Glycemic Control in Type 2 Diabetes: As an adjunct to diet and exercise to lower blood sugar levels in adults with Type 2 Diabetes Mellitus.
Chronic Weight Management: As a highly targeted metabolic therapeutic to assist in substantial and sustained long-term weight reduction in adults presenting with obesity or overweight comorbidities.
Obstructive Sleep Apnea (OSA): To manage moderate-to-severe OSA linked to underlying obesity.
Limitations of Use:
It has not been clinically evaluated in patients with a history of acute or chronic pancreatitis.
It is not indicated for the treatment of patients with Type 1 Diabetes Mellitus.
Mechanism of Action
Tirzep combines the power of two critical metabolic incretins into a single active molecule:
Dual Incretin Receptor Targeting: It selectively binds to and activates both native GIP and GLP-1 receptors.
Glucose-Dependent Insulin Management: It enhances both first- and second-phase insulin secretion from pancreatic beta cells while lowering glucagon secretion. Because this action occurs strictly in a glucose-dependent manner, it works robustly when blood sugar is high and minimizes the baseline risk of hypoglycemia.
Satiety and Gastric Regulation: Tirzep stabilizes postprandial glucose levels by delaying gastric emptying and acting directly on CNS satiety centers to suppress appetite, thereby reducing total caloric intake.
Pharmacokinetic Profile
Distribution & Half-Life: Thanks to its specialized fatty diacid moiety, Tirzep binds extensively to plasma albumin, resulting in an elimination half-life of approximately 5 days. This allows for a consistent, once-weekly injection cycle.
Metabolism: Metabolized safely via proteolytic cleavage of its peptide backbone, beta-oxidation of its fatty acid chain, and general amide hydrolysis.
Dosage & Administration
Route of Administration: Strictly via subcutaneous injection in the abdomen, thigh, or upper arm. Never inject intravenously or intramuscularly.
Titration Protocol: Therapy is initiated at a low introduction tier of 2.5 mg once weekly for 4 weeks (to minimize GI acclimation), escalating in 2.5 mg steps every 4 weeks. 10 mg once weekly is a highly effective target maintenance dose. The maximum dosage is 15 mg once weekly.
Flexible Execution: Can be injected at any time of day, with or without meals. Rotate the injection site with every dose. If used alongside insulin, administer them as separate injections; never mix them in the same syringe.
Missed Dose Window: If a dose is missed, administer it as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip the missed dose and resume on your regular weekly schedule day.
Clinical Considerations & Safety
Risk of Thyroid C-Cell Tumors (Boxed Warning): Tirzepatide is strictly contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pancreatitis Vigilance: Patients must be observed for persistent, severe abdominal pain radiating to the back. Discontinue immediately if pancreatitis is suspected.
Gastrointestinal Reactions: Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain are common.
Delayed Gastric Emptying (Drug Interactions): Tirzep has the potential to impact the absorption rates of concurrent oral medications. Monitor drugs with a narrow therapeutic index (e.g., warfarin) closely.
Oral Contraceptive Alert: Due to absorption delays, patients using oral hormonal contraceptives should switch to a non-oral birth control method or add a secondary barrier method for 4 weeks after starting treatment and for 4 weeks following each subsequent dose escalation.
Storage: Keep refrigerated at 2°C to 8°C. Protect from light. Do not freeze—if a pre-filled syringe has been frozen, it must be discarded.
Latex Caution: The needle cover of the pre-filled syringe contains dry natural rubber (a latex derivative), which may trigger allergic reactions in sensitive individuals.
Commercial Pack: Tirzep 10 mg is packaged as a precise 0.5 ml sterile solution inside a single-dose pre-filled syringe, complete with a first-aid bandage and an alcohol pad for immediate preparation.